Valuation: Keros Therapeutics, Inc.

Market Cap 210M 180M 169M 155M 291M 20.11B 296M 1.99B 779M 10.08B 790M 773M 33.34B P/E 2026 *
-1.95x
P/E 2027 * -1.69x
Enterprise Value 210M 180M 169M 155M 291M 20.11B 296M 1.99B 779M 10.08B 790M 773M 33.34B EV / Sales 2026 *
12.8x
EV / Sales 2027 * 16.6x
Free-Float
46.47%
Yield 2026 *
-
Yield 2027 * -
1 day+2.83%
1 week-2.81%
Current month+8.09%
1 month+2.59%
3 months+9.84%
6 months-34.23%
Current year-46.54%
1 week 10
Extreme 10
11.43
1 month 9.69
Extreme 9.69
11.43
Current year 9.69
Extreme 9.69
20.34
1 year 9.69
Extreme 9.69
22.55
3 years 9.12
Extreme 9.12
73
5 years 9.12
Extreme 9.12
73
10 years 9.12
Extreme 9.12
88.8
Manager TitleAgeSince
Chief Executive Officer 70 01/12/2015
Director of Finance/CFO 55 03/08/2026
Chief Tech/Sci/R&D Officer 53 01/06/2019
Director TitleAgeSince
Chairman 70 01/07/2024
Director/Board Member 63 01/04/2016
Director/Board Member 50 01/03/2020
Date Insider Type Main position Quantity % Market Cap.
8/4/26 A Other

Chief Financial Officer

117,468 0.5935%
7/15/26 A Buy

Chairman

1,000 0.0051%
7/1/26 A Free

Director

28,656 0.1448%
Change 5-day change 1-year change 3-year change Capi.($)
+2.83%-2.81%-24.88%-69.44% 210M
-1.90%+2.37%+69.11%+110.88% 73.45B
+0.87%+15.32%+56.99%+92.41% 62.99B
+0.46%-2.64%+1.24%+485.39% 28.05B
-1.40%+4.18%+54.52%+19.60% 25.42B
+20.95%+19.55%-0.47%-5.66% 23.3B
+2.28%+5.65%+42.00%-13.75% 19.45B
0.00%-4.11%+243.99%+423.83% 18.16B
-3.50%-0.95%+17.17%+534.55% 16.53B
+2.46%+7.95%+44.95%+154.49% 13.16B
Average +2.30%+2.44%+50.46%+173.23% 28.07B
Weighted average by Cap. +1.43%+4.38%+57.69%+164.69%

Financials

2026 *2027 *
Net sales 16.37M 14.04M 13.11M 12.03M 22.62M 1.56B 23M 155M 60.59M 785M 61.47M 60.13M 2.59B 12.64M 10.84M 10.12M 9.29M 17.46M 1.21B 17.75M 119M 46.76M 606M 47.44M 46.41M 2B
Net income -108M -93.02M -86.86M -79.69M -150M -10.36B -152M -1.02B -401M -5.2B -407M -398M -17.19B -147M -126M -118M -108M -203M -14.06B -207M -1.39B -544M -7.05B -552M -540M -23.31B
Net Debt - -
Logo Keros Therapeutics, Inc.
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, elritercept (KER-065), is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, and in patients with myelofibrosis. KER-065 is designed to act as a ligand trap and inhibit the biological effects of myostatin and activin A. Its lead product candidate, rinvatercept, is being developed for the treatment of neuromuscular diseases. Elritercept is designed to raise red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-B family of proteins to promote hematopoiesis.
Employees
92
Date Price Change Volume
19/08/26 $10.87 +2.45% 68,658
18/08/26 $10.61 +1.24% 256,149
17/08/26 $10.48 +3.76% 221,513
14/08/26 $10.10 -5.25% 315,284
13/08/26 $10.66 -4.82% 239,468
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
10.61USD
Average target price
19.83USD
Spread / Average Target
+86.93%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. KROS Stock